Pfizer succeeds in mid-stage trial for breast cancer therapy

Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a mid-stage trial for certain patients with ...

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...
Cadillac News

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

Pfizer Leans On Obesity And Immunology To Refresh Growth Story

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

Argus turns bullish on Pfizer (PFE), highlights GLP-1 and oncology pipeline

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Dividend Stocks to Invest in Under $50. On March 2, Argus upgraded Pfizer Inc. (NYSE:PFE) to Buy from Hold. The firm set a $35 price target on the ...